Compound Guide
What Is Semaglutide? Research Overview
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has been extensively studied in metabolic research. This guide covers its structure, mechanism, and research context. For laboratory research reference only — not for human use.
Research Use Only: Semaglutide supplied by TrueCanPeptides is for qualified in vitro laboratory research. Not an approved drug for general sale. Not intended for human or animal administration.
What Is Semaglutide?
Semaglutide is a synthetic analogue of human glucagon-like peptide-1 (GLP-1), a 30-amino-acid incretin hormone naturally secreted by L-cells of the intestinal mucosa in response to nutrient ingestion. The synthetic version incorporates structural modifications to extend its biological half-life from the native GLP-1’s approximate 2-minute plasma half-life to approximately 7 days in human pharmacological studies.
The primary modification involves C-18 fatty diacid conjugation via a linker at lysine residue 34, enabling albumin binding and substantially slowing renal clearance and proteolytic degradation. A substitution at position 8 (alanine to α-aminoisobutyric acid) provides resistance to DPP-4 cleavage — the enzyme responsible for rapid degradation of native GLP-1.
Mechanism of Action
Semaglutide functions as a full agonist at the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor expressed in pancreatic beta cells, the central nervous system, the gastrointestinal tract, and cardiac tissue. GLP-1R activation initiates a cAMP-dependent signalling cascade that modulates multiple downstream targets.
| Tissue / System | Investigated Effect (Preclinical/Clinical) |
|---|---|
| Pancreatic beta cells | Glucose-dependent insulin secretion stimulation; beta-cell proliferation in animal models |
| Central nervous system | Hypothalamic satiety signalling; appetite suppression pathways |
| Gastric system | Delayed gastric emptying; reduced nutrient absorption rate |
| Cardiovascular | Endothelial function; atherosclerosis models; MACE endpoint studies |
| Hepatic | Lipid metabolism; hepatic steatosis models |
Semaglutide Structure and Chemistry
Semaglutide is a 31-amino-acid peptide (one additional residue compared to native GLP-1(7-36)) with a molecular formula of C₁₈₇H₂₉₁N₄₅O₅₉ and a molecular weight of approximately 4,113 Da. Its sequence is closely related to native GLP-1 with two key substitutions and the C-18 fatty acid side chain modification.
The compound is supplied as a white to off-white lyophilized powder. It is water-soluble and typically reconstituted with bacteriostatic water or sterile saline for laboratory use. Solubility characteristics vary with pH; optimal dissolution is generally achieved at neutral to slightly alkaline pH.
Semaglutide in Research Literature
Semaglutide has one of the most extensively studied research profiles of any GLP-1 analogue. The SUSTAIN and STEP clinical trial programmes generated a large body of peer-reviewed literature on its metabolic and cardiometabolic effects in human subjects. Preclinical research using rodent models preceded these trials and continues to be conducted in parallel, exploring cellular mechanisms not fully accessible in human trials.
Research areas where semaglutide has been investigated include: metabolic syndrome models, non-alcoholic fatty liver disease (NAFLD/NASH) animal models, neurological inflammation models, and addiction/reward pathway research (given GLP-1R expression in dopaminergic areas).
Comparison with Other GLP-1 Research Compounds
Semaglutide is a GLP-1 monoagonist. Newer research compounds have expanded receptor targeting beyond GLP-1R alone — tirzepatide adds GIP receptor co-agonism (dual agonist), while retatrutide adds glucagon receptor activity to the dual target of tirzepatide, making it a triple agonist. Each generation expands the mechanistic research scope.
📊 See our detailed receptor comparison: Semaglutide vs Tirzepatide vs Retatrutide →
Storage and Handling
As a lyophilized peptide, semaglutide should be stored at −20°C, protected from light and moisture, in a sealed container. Once reconstituted, the solution should be used promptly or aliquoted and stored at −80°C. Avoid repeated freeze-thaw cycles. See the Peptide Storage Guide for full protocol.
FAQs
Is semaglutide a peptide?
Yes. Semaglutide is a 31-amino-acid peptide analogue of the endogenous incretin GLP-1 (glucagon-like peptide-1). It belongs to the class of GLP-1 receptor agonists — peptide-based compounds that mimic and extend the action of native GLP-1.
What is the difference between semaglutide and tirzepatide?
Semaglutide targets only the GLP-1 receptor (monoagonist). Tirzepatide targets both GLP-1R and GIP receptor (dual agonist). This expanded receptor profile gives tirzepatide a distinct and reportedly more potent metabolic research profile in clinical studies. See the full comparison here.
Can semaglutide be purchased in Canada for research?
TrueCanPeptides supplies semaglutide as a research compound for qualified in vitro laboratory use. It is not supplied as a pharmaceutical or for therapeutic administration. Researchers are responsible for institutional compliance. See our Research Peptides Canada guide.
Semaglutide is supplied by TrueCanPeptides for qualified in vitro laboratory research only. Not intended for human or animal administration. Not evaluated or approved by Health Canada for any medical use. The research literature referenced is provided for educational context only.
Related: Semaglutide 10mg | Sema vs Tirze vs Reta | Sema vs Tirze (Canada) | What Are Peptides?